October 25th 2024
Zanubrutinib, obinutuzumab, and venetoclax delivered promising response and survival data for the treatment of patients with mantle cell lymphoma harboring a TP53 mutation.
Triplet Combination Addresses Unmet Need in Small Study Population With Mantle Cell Lymphoma
May 14th 2022Study results may indicate for a potential alternative treatment option to address the unmet needs for elderly patients with newly diagnosed mantle cell lymphoma, according to Michael Wang, MD.
Watch
Global ZILO-301 Study of Zilovertamab for MCL to Initiate in Q3 2022
April 28th 2022Oncternal Therapeutics announced it would terminate its study of ONCT-216 for patients with Ewing sarcoma and prioritize its phase 3 ZILO-301 study of zilovertamab plus ibrutinib for patients with relapsed/refractory mantle cell lymphoma.
Read More
Approval Sought for Ibrutinib Combination in Patients With Mantle Cell Lymphoma
April 5th 2022An application seeking the approval of a new indication for the combination of ibrutinib, bendamustine, and rituximab in adult patients with previously untreated mantle cell lymphoma has been submitted.
Read More
ViPOR Regimen Signals Benefit in Patients With Mantle Cell Lymphoma
February 7th 2022In an interview with Targeted Oncology, Christopher Melani, MD, discussed the ongoing ViPOR study exploring a Bruton’s tyrosine kinase inhibitor and BCL2 inhibitor, and NF-κB survival pathway activating combination.
Read More
BTK Inhibitors Continue to Offer Chemotherapy-Free Options for MCL Treatment
January 18th 2022At the 63rd ASH Annual Meeting and Exposition, studies highlighted the promise of Bruton's tyrosine kinase inhibitors for the treatment of patients with mantle cell lymphoma and what oncologists should do after Bruton's tyrosine kinase inhibition.
Read More
Acalabrutinib Plus Venetoclax and Rituximab Signals Safety, Efficacy in MCL
January 11th 2022In an interview with Targeted Oncology, Michael Wang, MD, a professor in the department of lymphoma and myeloma at MD Anderson Cancer Center, discussed the safety, efficacy, and tolerability of acalabrutinib plus venetoclax and rituximab in mantle cell lymphoma.
Read More
Pirtobrutinib Treatment in MCL Models Overcome Resistant to Ibrutinib/Venetoclax
December 13th 2021The novel non-covalent BTK inhibitor pirtobrutinib has shown encouraging preclinical efficacy in addressing resistance to ibrutinib and venetoclax resistance in mantle cell lymphoma models cell lines.
Read More
FDA Considers Parsaclisib for Approval in FL, MZL, and MCL
November 1st 2021The FDA is considering an application parsaclisib as treatment of patients with relapsed or refractory follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma, and granted priority review for 2 of the 3 indications.
Read More